| Expression pattern: |
DN |
| Associated gene: |
FGF1, AMPK |
| Associated microRNA: |
miRNA-326 |
| Biological function: |
Alleviates hepatic lipid accumulation and intrahepatic lipid deposition in MASLD. |
| Molecular mechanism: |
Acts as a ceRNA by sponging miRNA-326 to relieve suppression of FGF1 and activate AMPK signaling. |
| Biological pathway or process: |
AMPK (promotes); lipid metabolism (other); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; Bioinformatics Analysis; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Luciferase Reporter Assay; RNA Pull-Down; Transfection; Oil Red O Staining; ELISA; Western Blot; IF (Immunofluorescence); In Vivo Animal Model; H&E Staining |
| Clinical significance: |
Potential as a diagnostic biomarker and therapeutic target for MASLD. |
| Description: |
circZBTB46 is down-regulated in MASLD/MASH liver tissues and in experimental steatosis models. It reduces hepatic lipid accumulation by sponging miRNA-326, restoring FGF1 expression and increasing AMPK activation (phosphorylation). |
| Confidence score: |
0.7825 |